X

The Lancet Oncology

The Lancet Oncology
Pembrolizumab Plus Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Given each drug's single agent activity and unique mechanism of action, this study aims to evaluate the anti-tumour activity of PD-1 blockade with EGFR inhibition in recurrent or metastatic HNSCC.<

The Lancet Oncology
05/11/2021
Efficacy and Safety of Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

This study evaluates the efficacy and safety of tisotumab vedotin, a tissue factor-directed antibody–drug conjugate, in this patient population.

The Lancet Oncology
05/01/2021
Second-Line FOLFOX Chemotherapy versus Active Symptom Control for Advanced Biliary Tract Cancer

The aim of this study is to determine the benefit derived from second-line FOLFOX chemotherapy in advanced biliary tract cancer.

The Lancet Oncology
05/01/2021
Safety and Immunogenicity of One versus Two Doses of the COVID-19 Vaccine BNT162b2 for Patients With Cancer

This study examines the safety and immunogenicity of the BNT162b2 vaccine in patients with cancer.

The Lancet Oncology
04/27/2021
Secondary Cytoreduction Followed By Chemotherapy Versus Chemotherapy Alone in Platinum-Sensitive Relapsed Ovarian Cancer

Study investigators assess the efficacy of secondary cytoreduction plus chemotherapy versus chemotherapy alone in this patient population.

The Lancet Oncology
04/01/2021
Olaparib Tablets as Maintenance Therapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a BRCA1/2 Mutation

The aim of this final analysis is to investigate the effect of olaparib on overall survival.

The Lancet Oncology
03/18/2021
Secondary Cytoreduction Followed By Chemotherapy Versus Chemotherapy Alone in Platinum-Sensitive Relapsed Ovarian Cancer (SOC-1)

Study investigators assess the efficacy of secondary cytoreduction plus chemotherapy versus chemotherapy alone in this patient population.

The Lancet Oncology
04/01/2021
Cetuximab, Docetaxel, and Cisplatin versus Platinum, Fluorouracil, and Cetuximab as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma

Results from a phase 2 trial of the TPEx chemotherapy regimen show promising results, with a median overall survival of 14·0 months in first-line recurrent or metastatic HNSCC.

The Lancet Oncology
04/01/2021
MRI-Guided Adaptive Brachytherapy in Locally Advanced Cervical Cancer (EMBRACE-I)

This study reports on EMBRACE-I, which aims to evaluate local tumor control and morbidity after chemoradiotherapy and MRI-based IGABT.

The Lancet Oncology
04/01/2021
Olaparib Tablets as Maintenance Therapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a BRCA1/2 Mutation

The aim of this final analysis is to investigate the effect of olaparib on overall survival.

The Lancet Oncology
03/18/2021
Subscribe to The Lancet Oncology

source list reference

#7d60d9
#2694a4
#32a887
#85eb24
#352625
#4d4537
#d2093c
#8e3f1c
#76b6c3
#bfcfc8
#c61417
#67e25b
#efef71
#03cffc
#42fc9a
#cc529a
#c59445
#c8cc0c
#bf6be3
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
#a153ac
#e7f6e3
#6fc969
#9a8c2c
#a9c507
#2b9ab3
#e61923
#990677
#4a7bab
#89f67c
#49a21d
#2c990a
#d7da81
#575662
#a60538
#49cde9
#c20fce
#d95d39